Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer
Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer
复制标题
DOI：
10.1016/j.biomaterials.2015.03.024
复制
发表时间：
2015-06-01
期刊：
影响因子：
14
通讯作者：
Cui, Daxiang
中科院分区：
文献类型：
--
作者：
Li, Chao;Liang, Shujing;Cui, Daxiang
树突状细胞（Dendritic cells，DCs）在肿瘤免疫中显示出良好的应用前景。如何增强DCs的免疫调节作用，在肿瘤的靶向免疫治疗和预防中仍是一个巨大的挑战。本文首次报道了同种异体DC与肿瘤细胞融合疫苗联合细胞因子诱导的杀伤细胞（cytokine induced killing cells，CIK）用于胃癌的靶向显像和增强免疫效果。通过PEG介导的成熟DC与失活胃癌细胞MGC803融合制备融合疫苗。在荷瘤、术后和无瘤小鼠模型中评价融合细胞（FC）的免疫和预防潜力。利用实时动物成像系统研究了近红外区量子点标记的FC的迁移和归巢过程。结果表明，FC和FC + CIK在体内均能激活肿瘤特异性CTL，主动靶向肿瘤组织，增强肿瘤预防作用，显著抑制肿瘤生长。并对可能的机理进行了探讨。结论：同种异体DC与肿瘤细胞融合疫苗可用于胃癌的靶向显像和增强免疫效果，FC + CIK策略在胃癌的早期治疗和预防肿瘤转移复发等临床应用中具有广阔的前景。(C)2015爱思唯尔有限公司版权所有。
Dendritic cells (DCs) have displayed the promising potential in cancer immunity. How to enhance DCs immunotherapeutic effect in cancer targeted immunotherapy and prevention is still a great challenge. Herein, we report for the first time the allogenic DCs and tumor cell fused vaccine combined with cytokine induced killing cells (CIKs) for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer (GC). The fused vaccine was prepared by PEG mediated fusion between mature DCs and inactive gastric cancer MGC803 cells. The immunotherapeutic and prophylactic potential of the fused cells (FCs) were evaluated in tumor-bearing, post-surgery and tumor free mice models. The migration and homing process of near infrared region quantum dots (NIR-QDs) labeled FCs were investigated by real-time animal imaging system. Results showed that the FCs and FC + CIKs could trigger the tumor-specific CTLs against GC cells, target the tumor tissue initiatively and enhance the prophylactic effects, suppress the tumor growth remarkably in vivo. The potential mechanism is also investigated. In conclusion, allogenic DCs and tumor cell fused vaccine can be used for targeted imaging and enhanced immunotherapeutic efficacy of GC, and the FC + CIKs strategy own great potential in clinical applications such as early therapy and prevention of tumor-metastasis and relapse in near future. (C) 2015 Elsevier Ltd. All rights reserved.